Carcinoid Syndrome Market Insights, Emerging Therapy, and Market Report 2032

DelveInsight’s Carcinoid Syndrome Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Carcinoid Syndrome market share of the individual therapies, current and forecasted Carcinoid Syndrome market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Carcinoid Syndrome Overview

Carcinoid syndrome is the collection of symptoms some people get when a neuroendocrine tumour, usually one that has spread to the liver, releases hormones such as serotonin into the bloodstream. It is predominantly associated with neuroendocrine tumors (NETs) that arise from the mid-gut in the setting of extensive liver metastases but may be present in patients with bronchial carcinoids, and more rarely, in patients with pancreatic NETs.

 

Download Sample Report @ Carcinoid Syndrome Market

 

 

Some of the key features of the Carcinoid Syndrome Market Report

It was found that the patients with carcinoid syndrome were more frequently female than male.
Estimates that 27 new cases of Carcinoid Tumour per million are diagnosed in the United States per year out of which, only about 10% develops carcinoid syndrome.
The incidence of Carcinoid Syndrome in Europe is 16%, and various symptoms included were: diarrhea (91%), flushing (89%), wheezing (22%), and carcinoid heart disease (CHD; 35%).
Carcinoid Syndrome companies such as Novartis Pharma, Lexicon, Aquestive Therapeutics, and several others.
Carcinoid Syndrome therapies such as Somatostatin LAR, Xermelo, AQST-305, and several others.

 

Carcinoid Syndrome Symptoms

The symptoms of carcinoid syndrome include episodes of warmth and redness of the face, head and upper chest; diarrhea; marked changes in blood pressure (usually hypotension, a decrease in blood pressure); asthmatic-like wheezing; weight loss or gain; malnutrition; dehydration; weakness; muscle and joint aching; and peptic ulcer.

 

Carcinoid Syndrome Causes

It is caused by a carcinoid tumor that secretes serotonin or other chemicals into your bloodstream.

 

Carcinoid Syndrome Market Insights

Carcinoid syndrome is the term applied to a constellation of symptoms that are mediated by various hormones that are secreted by some NETs. Two of the most common manifestations are flushing and diarrhea. Symptoms are associated with elevations in serum serotonin or its metabolite urinary 5-hydroxyindoleacetic acid (5-HIAA).

 

Carcinoid Syndrome Treatment

The current treatment pattern of Carcinoid Syndrome involve medications to control the specific signs and symptoms and surgery at an early stage can lead to the complete cure of disease. There are different treatment modalities for carcinoid syndrome which include Somatostatin Analogs, Liver-Directed Treatment Therapy, and Surgical Debulking for early-stage low-grade neuroendocrine tumors, and Chemotherapy for the treatment of poorly differentiated neuroendocrine tumors or refractory Carcinoid Syndrome.

 

Carcinoid Syndrome Epidemiology Segmentation

Total Incident Cases
Symptom-specific Incident Cases
Gender-specific Incident Cases
Treatable Cases

 

Carcinoid Syndrome Emerging Therapy Assessment

The development of new drugs for Carcinoid Syndrome is analyzed by highlighting the recent insights into the pathophysiological mechanisms of the disease. Some of the key players including Aquestive Therapeutics, and others are developing drugs for the treatment of Carcinoid Syndrome.

 

Get an overview of the report @ Carcinoid Syndrome Market Report

 

Table of Content

1. Key Insights

2. Executive Summary of Carcinoid Syndrome

3. Competitive Intelligence Analysis for Carcinoid Syndrome

4. Carcinoid Syndrome: Market Overview at a Glance

5. Carcinoid Syndrome: Disease Background and Overview

6. Patient Journey

7. Carcinoid Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Carcinoid Syndrome Unmet Needs

10. Key Endpoints of Carcinoid Syndrome Treatment

11. Carcinoid Syndrome Marketed Products

12. Carcinoid Syndrome Emerging Therapies

13. Carcinoid Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Carcinoid Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

info@delveinsight.com

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/